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Abstract
Streptococcus mutans and Helicobacter pylori belong to the most common bac-
terial pathogens of humans. They infect more than 50% of the world’s popula-
tion. Further, enterotoxigenic Escherichia coli (ETEC) is regarded as the most 
common bacterial cause of diarrhoea worldwide. 
Colostrum is essential for a newborn by providing nutrition but also immuno-
logical protection. Immunoglobulins and complement system are considered as 
the major antimicrobial agents in bovine colostrum. By immunizing a cow it is 
possible to produce specific antibodies in serum and lacteal secretions against 
microbes. These antibodies have proven effective in preventing many gastroin-
testinal microbial diseases. Probiotic bacteria are often used in fermented dairy 
products because of their beneficial effects on human health. Some probiotic 
bacteria, especially lactobacilli, can inhibit growth and colonization of patho-
gens. Probiotic bacteria like Lactobacillus rhamnosus GG (LGG) also reduce 
the side effects of antibiotic treatment. 
The aims of this study were to investigate the effects of bovine colostrum and 
specific colostral antibodies, and some lactic acid bacteria on gastrointestinal 
infections, especially H. pylori induced gastritis and dental caries caused by S. 
mutans. The effect of colostrum on the activity of the complement system in 
neonatal calves was also studied.
It was possible to increase substantially complement and opsonization activities 
of serum by feeding colostral whey concentrate to neonatal calves. A colostral 
immune preparation (IP) containing specific antibodies against H. felis prevented 
but did not eradicate an experimental H. felis infection in mice. However, the 
IP combined with amoxicillin lowered the level of inflammation and coloniza-
tion more than amoxicillin alone. The specific anti-cariogenic antibodies of IP 
remained active and functional when added to UHT milk or fermented with 
LGG and stored for an extended time. Further, the combination of IP and LGG 
prevented the adherence of S. mutans effectively.
Lactobacillus plantarum MLBPL1 isolated from sauerkraut showed anti-Helico-
bacter activity mainly associated with cell wall, from where it can be extracted 5
into the culture supernatant. Colostral preparations, and acidifying microbes (L. 
plantarum MLBPL1 and LGG) reduced the adhesion of H. pylori on human gas-
tric adenocarcinoma cells. They also reduced the IL-8 production of the infected 
cells. IL-8 secretion is a primary response to H. pylori infection.
Supplementation of an antibiotic treatment with a food product containing 
probiotic lactobacilli and/or IP could offer a potential complementary means to 
suppress gastrointestinal infections.
Key-words: colostrum, lactic acid bacteria, infections6
Abbreviations frequently used in the text
AGS cells      Human gastric adenocarcinoma cells
ATP      Adenosine triphosphate
EGTA      Ethylene glycol tetraacetic acid
ETEC      Enterotoxigenic Escherichia coli
FBS      Fetal bovine serum
cfu       Colony forming units
CL       Chemiluminescence
CP        Colostral control preparation
ELISA      Enzyme linked immunosorbent assay
HBSS      Hank’s balanced salt solution
IgG       Immunoglobulin G
IFN        Interferon
IL        Interleukin
IP        Colostral immune preparation with   
        specific antibodies
LAB      Lactic acid bacteria
LG21       Lactobacillus gasseri OLL2716
LGG      Lactobacillus rhamnosus GG
LPS      Lipopolysaccharide
MBL      Mannose binding lectin
NBS      Normal bovine serum
NF-κB      Nuclear factor κB
PBS      Phosphate buffered saline
TGF      Transforming growth factor  
TLR      Toll like receptor
TNF      Tumor necrosis factor
UHT      Ultra-high temperature7
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Introduction 1 
Epithelial cells of skin, lungs and gastrointestinal tract are the first barriers 
against the attacks by foreign invader like pathogens. The body fluids like sa-
liva, tears, milk, and mucosal secretions contain lysozyme, lactoferrin and ot-
her unspecific antibacterial molecules. Gastric and bile acids as well as gastric 
enzymes are lethal for many bacteria. Complement, cytokines, chemokines, in-
terferons etc. are also included in the defense mechanisms of the innate immune 
system. Normal flora of the skin and gut are extremely important in keeping the 
number of possible pathogens low for instance by preventing their colonization. 
Many microbes have in their membrane structures that receptors of phagocytes 
recognize and help them to ingest the foreign cells. Some bacteria have a capsu-
le structure that prevents the phagocytes recognizing them. If the innate immu-
ne system is insufficient the adaptive immune system is needed. Adaptive im-
munity recognizes antigenic structures as non-self. Antibodies and the classical 
route of complement system are central for the adaptive immune system.
Streptococcus mutans and Helicobacter pylori belong to the most common bac-
terial pathogens of humans. They infect more than 50% of the world’s popula-
tion. Further, enterotoxigenic Escherichia coli (ETEC) is regarded as the most 
common bacterial cause of diarrhoea worldwide (Walker et al. 2007).  
Common to the infections caused by S. mutans and H. pylori is that antibiotic 
treatments are not the choice to treat all people suffering from these disorders. 
The development of a vaccine against these pathogens has so far not been suc-
cessful (Aebischer et al. 2008, Loimaranta 1999). Other means to control the-
se pathogens are thus needed. During last decades the use of probiotic bacteria 
and passive immunization by oral administration of specific antibodies against 
gastrointestinal diseases has gained a lot of attention. 
The concept of probiotics was born in 1907 when Ilya Metchnikoff supposed 
that Bulgarians live longer than other populations because of their consumpti-
on of fermented milk products with viable bacteria. He believed that harmless 
bacteria of fermented products competed with pathogens. During the past de-
cade there has been a near exponential increase in publications on probiotics 
(reviewed by Meurman 2005).
The history of the concept “immune milk” started in 1950’s when Petersen and 
Campbell suggested that orally administered bovine colostrum could provide 
passive immune protection for humans. Since 1980’s an increasing number of 
studies has emerged on the effect of specific milk or colostrum derived antibo-
dies from immunized cows in treatment or prevention of various gastrointesti-
nal diseases (Korhonen and Marnila 2006).11
In this study the efficacy of bovine colostrum, specific colostral antibodies, and 
some lactic acid bacteria were investigated on gastrointestinal infections, espe-
cially Helicobacter induced gastritis and dental caries. The effect of colostrum 
on the activity of complement system in neonatal calves was also studied.12
Review of the literature 2 
Basic concepts of immunology 2.1 
Antibodies 2.1.1 
Antibodies or immunoglobulins are produced by B-lymphocytes. The basic 
structure of immunoglobulin molecule is composed of two identical light chains 
and two identical heavy chain joined together with disulphide bonds (Figure 1). 
The antigen binding sites are located in the Fab region in the N-terminal “arms” 
of the Y-shaped flexible molecule. Generally, each antibody can bind specifi-
cally to only one antigen. Fc portion interacts with cells of the immune system 
and activates the complement mediated bacteriolytic reactions. The molecular 
weight of the basic structure of immunoglobulin molecule is about 160 000 Dal-
tons. IgM is a pentamer of the basic structure. It is the first class of antibodies to 
appear in the serum after injection of an antigen, and is especially efficient with 
complement-mediated lysis. IgG is the major antibody in the serum and bovine 
milk. It has four subclasses differing mainly in the number of disulphide bonds. 
IgGs are able to inactivate toxins, aggregate and opsonise parasites, and activate 
the complement system. IgA is a monomer in human serum but dimer in other 
mammals. The dimeric IgA is the major class of immunoglobulins in external 
secretions such as saliva, tears, intestinal mucus, and milk, the ruminal milk 
being an exception with IgG1 as the major class of immunoglobulins. It agglu-
tinates antigens, binds viruses and toxins, and prevents the adhesion of entero-
pathogenic bacteria to mucosal epithelial cells. The other two classes of immu-
noglobulins are IgD whose specific role is not known (Vladutiu 2000), and IgE, 
involved in protection against parasites, as well as in allergic reactions.
Figure 1. Basic structure of immunoglobulin molecule.
Fab 
Fc 
Antigen binding sites 13
Complement system 2.1.2 
The main functions of the complement system are to eliminate foreign patho-
gens by causing cytolytic membrane lesions, to opsonize microbes, and to me-
diate an inflammatory reaction. The complement system is present in serum, 
and also in bovine colostrum (reviewed by Korhonen et al. 2000b).  The comple-
ment system is composed of more than 20 proteins and regulatory components. 
Activation of the complement system can occur via three pathways (Figure 2) 
in a sequential manner by proteolytic cleavages and association of precursor 
molecules.
The classical pathway of complement uses antibodies, mainly IgM, for the re-
cognition of foreign cells. The binding of the C1 complex to antigen-antibody 
complexes initiates proteolytic cleavage of complement components C4 and C2 
by C1s, leading to the formation of a C4b2a enzyme complex, the C3 converta-
se of the classical pathway (Markiewski and Lambris 2007, Figure 2). The lec-
tin pathway begins with binding of the complex mannose-binding lectin (MBL) 
and mannose-binding lectin-associated proteases 1 and 2 to a bacterial cell wall 
which leads to the formation of the C3 convertase. The alternative pathway is 
initiated by binding to surfaces lacking complement regulatory proteins. Spon-
Classical 
C1q/C1r/C1s 
C4 
Lectin 
MBL/MASP-1/MASP-2 
C4a 
C4b + C2 
C4b2a  
(C3-convertase) 
C3  C5 
C3bBb3b  
(C5-convertase) 
C4b2a3b  
(C5-convertase) 
C3bBb-P 
P, D 
+  C3b  C3a  C5b  C6-9  C5b-9 (MAC) 
C5a 
Alternative 
C3(H2O) + B 
Ba 
C3(H2O) Bb  
(C3-convertase)  
C3b + B 
D 
C3 
Lysis of 
bacteria 
Inflammation 
Figure 2. Schematic presentation of the complement cascade (modified from 
Thurman and Holers 2006). C1-C9 represent complement component molecu-
les, MBL mannose-binding lecting, MASP mannose-binding lectin associated 
protease, P properdin, MAC membrane attack complex.14
taneous hydrolysis of C3 leads to the formation of C3(H2O) which forms a 
complex with factor B, followed by the cleavage of factor B within this comp-
lex by factor D. The final product of these enzymatic reactions is the C3(H2O)
Bb complex. It is stabilized by properdin and works as a C3 convertase. 
C3 convertases generated through various pathways cleave C3 to C3a and C3b. 
C3b contributes to the formation of the C5 convertase, which cleaves C5 to C5a 
and C5b. Generated cleavage products function as opsonins augmenting phago-
cytosis, recruit leucocytes to the sites of inflammation and activate them. The 
complement cascade leads to membrane attack complex (MAC), the pores ge-
nerated leading to the death of the bacterial cell (Born and Bhakdi 1986).
All Gram-positive and several Gram-negative organisms are resistant to comple-
ment-mediated lysis. In these cases the opsonophago  cytosis is the main defen-
se mechanism (Rautemaa and Meri 1999). Opsonization means, “making ea-
table”, that is, augmenting the phagocytizing leukocytes to recognize, bind, ac-
tivate, ingest, and to kill the pathogen. During opsonization antibodies and/or 
complement molecules bind to antigens. Phagocytic cells recognize opsonized 
cells and ingest or destruct them. Bovine colostral antibodies are recognized 
by human phagocytes and thus have opsonizing activity also in humans (Loi-
maranta et al. 1999b).
Cytokines  and  chemokines  in  gastric  infec- 2.1.3 
tions
Epithelial and innate immune cells, e.g. macrophages, neutrophils and natural 
killer cells have receptors (like Toll-like receptors (TLR) and nucleotide-bin-
ding oligomerization domain (Nod) proteins) that recognize pathogen-asso-
ciated molecular patterns and mediate immune response (reviewed by Bodger 
and Crabtree 1998 and O’Keeffe and Moran 2008). Several TLRs with specific 
actions are known, for instance TLR4 that recognizes lipopolysaccharide (LPS) 
of Gram-negative bacteria, and TLR2 and TLR5 that recognize bacterial lipo-
peptides and flagellin, respectively (O’Keeffe and Moran 2008).
In infection, epithelial cells secrete chemokines and cytokines, such as tumor 
necrosis factor (TNF) –α, and interleukins (IL). TNF–α, IL-1, IL-6, and IL-8 
act as proinflammatory agents. Their production and expression is controlled 
by a transcription factor, nuclear factor (NF)-κB. The immunoinflammatory 
reaction is highly important in eliminating pathogens, but this reaction must be 
controlled to avoid a widespread or chronic inflammation. Immune response is 
down regulated by anti-inflammatory agents, e.g. IL-10.
Mononuclear phagocytes serve as a source of proinflammatory mediators and 
as antigen-presenting cells in early immune responses (Bodger and Crabtree 15
1998). NF-κB and IL-8 production in epithelial cells is dependent on signaling 
through Nod1 recognition of muropeptides (Viala et al. 2004).
Chemokines are involved in the recruitment and activation of specific immune 
cells. They can be distinguished to two subfamilies according to the arrange-
ment of two conserved cysteins (Baggiolini et al. 1995). The members of the C-
X-C subfamily (e.g. IL-8 and growth-related gene (GRO)-α) have specific che-
motactic activity for neutrophils, whereas the members of the C-C subfamily 
(e.g. RANTES (Regulated on activation, normal T expressed and secreted) and 
macrophage inflammatory protein (MIP)-1α) have effects on monocytes and 
lymphocytes (Baggiolini et al. 1995). 
T-cells are responsible for cell-mediated immunity and promote activation of 
many other immune cells and killing virally infected cells. T-cell differentiati-
on is induced by IL-12. T helper cells recognize peptides complexed to MHC 
class II molecules and secrete cytokines interferon-gamma (IFN-γ) and TNF–α 
that promote the proinflammatory immune response or IL-4, IL-5, and IL-13 
that induce B cells to produce antibodies (O’Keeffe and Moran 2008). Antigen 
specific regulatory T cells are crucial for the maintenance of tolerance to non-
pathogen antigens and for preventing the development of autoimmune diseases. 
They control and regulate inflammation and bacterial colonization. The sup-
pressive function of regulatory T cells is mediated via the production of IL-10 
or transforming growth factor (TGF)-β (O’Keeffe and Moran 2008).
Significance of colostrum in passive immunity 2.2 
Composition of bovine colostrum 2.2.1 
The milk secreted during the first five to seven days after delivery is called 
colostrum. The composition of colostrum differs from normal milk (Table 1). 
The total protein concentration is highest in the first two milkings after delive-
ry (over 15%), and then decreases rapidly (Parrish et al. 1950, Tsioulpas et al. 
2007, Kehoe et al. 2007). Lactose content in colostrum is lower than in normal 
milk, whereas colostrum contains more minerals, e.g. calcium (Tsioulpas et al. 
2007). Bovine colostrum contains 100 times more immunoglobulins than nor-
mal milk. They make up 70-80% of total protein in colostrum (Larson 1992). 
The major immunoglobulin classes in bovine colostrum are IgG, IgM, and IgA, 
IgG being the most abundant (Table 2).  16
Table 1. Mean values and standard deviation of fat, protein, lactose, and ash 
of bovine colostrum and milk samples (n=8) from the first 15 days of lactation 
(data from Tsioulpas et al. 2007).
Time (d) 
postpartum
Fat (%) Protein (%) Lactose (%) Ash (%)
1 3.55 ± 1.82 16.12 ± 1.64 2.69 ± 0.46 1.18 ± 0.17
2 3.49 ± 1.67 5.43 ± 0.24 3.04 ± 1.23 1.00 ± 0.11
3 4.50 ± 1.54 4.54 ± 0.40 3.52 ± 0.44 0.93 ± 0.05
4 4.26 ± 2.19 4.41 ± 0.31 3.82 ± 0.19 0.92 ± 0.08
5 3.89 ± 1.04 4.23 ± 0.24 4.15 ± 0.24 0.87 ± 0.04
15 3.66 ± 1.22 4.01 ± 0.43 4.32 ± 0.14 0.83 ± 0.04
Colostrum is also a rich source of various antimicrobial factors including lac-
toferrin, lysozyme, lactoperoxidase and complement components (Korhonen 
1977, Korhonen et al. 1995, Table 2). The most abundant and well-characterized 
growth factors in bovine colostrum are insulin-like growth factors (IGF-1 and 
IGF-2), insulin, TGF-β1, TGF-β2, and epidermal growth factors (EGF) (Pakka-
nen and Aalto 1997). Furthermore, milk proteins are a rich source of bioactive 
peptides (Korhonen and Pihlanto 2006, 2007). 
Function of colostrum  2.2.2 
The main purpose of colostrum is to offer the newborn adequate nutrition and 
immunological protection (Ehrlich 1892). It is essential for survival of calves 
because bovine placenta does not allow the transfer of immunoglobulins in sig-
nificant amounts (Larson et al. 1980). A sufficient intake of colostral immune 
components is important for calves in the long term as the overall health of cal-
ves fed immunoglobulin concentrate during the fist two days of life was better 
than in the normally fed control group during the first 30 days of life (Nousiai-
nen et al. 1994). Colostrum intake provokes drastic morphological and functio-
nal changes in the gastrointestinal tract of neonates.  If IgG1 concentrations in 
colostrum are low, high mortality rates of calves due to E. coli and other infec-
tions may result in. Non-nutrient factors of colostrum also modulate the micro-
bial flora of gastrointestinal tract (reviewed by Blum 2006). 17
Table 2. Concentration and potential biological functions of major proteins of 
bovine colostrum (Data from Korhonen and Pihlanto 2007, and Korhonen and 
Marnila 2006).
Protein
Concentration 
g/L
Biological functions
Caseins 26
Ion carrier, precursor for bioactive pep-
tides, immunomodulator
β-lactoglobulin 8.0
Retinol carrier, potential antioxidant, pre-
cursor for bioactive peptides, binds fatty 
acids
α-lactalbumin 3.0
Lactose synthesis in mammary gland, Ca 
carrier, immunomodulator, precursor for 
bioactive peptides, anticarcinogenic
Immunoglobulins 20-200
Specific immune protection, potential pre-
cursor for bioactive peptides
IgG1 •  15-180
IgG2 •  1-3
IgM •  3-9
IgA •  1-6
Glycomacropep-
tide
2.5
Antimicrobial, antithrombotic, bifidogen-
ic, gastric regulator
Lactoferrin 1.5
Antimicrobial, antioxidative, anticarcino-
genic, anti-inflammatory, iron transport, 
cell growth regulation, precursor for bio-
active peptides, immunomodulator
Lactoperoxidase 0.02
Antimicrobial, synergistic effect with im-
munoglobulins and lactoferrin
Lysozyme 0.0004
Antimicrobial, synergistic effect with im-
munoglobulins and lactoferrin
Serum albumin 1.3 Precursor for bioactive peptides
 
The potential biological functions of major colostral proteins are listed in Ta-
ble 2. Antibody-complement system is considered as the major antimicrobial 
agent in bovine colostrum (Korhonen et al. 2000a). The complement system of 
bovine colostrum is lytic against many pathogenic bacteria in vitro (Reiter and 18
Brock, 1975, Korhonen et al. 1995) but it is not known whether it is effective 
in vivo in the gut of the newborn calf (Korhonen et al. 2000a). Immunoglobu-
lins are able to opsonize bacteria, prevent the adhesion of microbes to surfac-
es, inhibit bacterial metabolism, agglutinate bacteria, and neutralize toxins and 
viruses (Korhonen and Marnila 2006). He et al. (2001) suggested that bovine 
colostrum might alter the human humoral immune responses in an adjuvant-
like manner. Colostral growth factors like IGF-1 and IGF-2 can stimulate cell 
growth as endocrine hormones via the blood and locally (Guimont et al. 1997). 
Colostral TGF-β has been found to increase IgA and IgG production in vitro 
(Chen and Li 1990).
Production of specific antibodies 2.2.3 
The antimicrobial activity of milk can be increased by systemic hyperimmuni-
sation of cows against a defined pathogen or a toxin at the end of the lactation 
period or during the dry period (Korhonen et al. 2000a,b). Different adjuvants 
have been used including Freund’s complete and incomplete adjuvant. Their 
use is, however, limited because of possible side effects. Aluminium-hydroxide 
based adjuvants have proven better for the health status of cows (Korhonen et 
al. 2000a). Both milk and colostrum have been used as a source of specific an-
tibodies. Colostrum is generally preferred because of its high concentration of 
IgGs, but on the other hand colostrum is secreted only for a limited time. 
Immunoglobulins can be isolated from colostral or milk whey in industrial scale 
by a number of methods, based on ultrafiltration or a combination of ultrafiltra-
tion and chromatography (Korhonen et al. 2000a). The recovery rate of immu-
noglobulins has varied from 40% to 70% (Elfstrand et al. 2002). With micro-
filtration (0.1µm) the recovery has reported to be over 90% (for review see Kor-
honen and Pihlanto 2007). Thermal treatments during processing may influen-
ce the stability of immunoglobulins. During storage in ambient or cold tempe-
rature the freeze dried immunoglobulin fractions retain their specific activity 
well for years (Korhonen et al. 2000a, Pant et al. 2007). The shelf life of bovine 
milk-based products containing antibodies can be prolonged by membrane filt-
ration (Fukumoto et al. 1994) or by fermentation processing.
Eggs are another source for specific antibodies. Immunized hen produce spe-
cific immunoglobulin Y (IgY) in the water-soluble part of egg yolk for months. 
IgY differs from mammal immunoglobulins by not being able to activate the 
complement system. Specific IgY has been produced and used successfully 
against a number of different antigens including E. coli, Salmonella, rotavirus, 
S. mutans, H. pylori, Pseudomonas aeruginosa, TNF-α, and various fish and 
other animal pathogens (Kovacs-Nolan et al. 2006).19
Applications of immune preparations 2.2.4 
The use of specific bovine colostral antibodies for promoting health of humans 
and animals has been studied since 1950’s (reviewed by Korhonen and Mar-
nila 2006). Passive immunization with specific antibodies provides an imme-
diate protection that is available also for persons with impaired immunity (Pant 
et al. 2007). Colostral and immune milk preparations against enteropathogenic 
E. coli, rotavirus, Cryptosporidium, Shigella flexneri, H. pylori, Vibrio chole-
rae, and caries-promoting streptococci have been studied in controlled clinical 
trials (see reviews by Korhonen et al. 2000a, and Korhonen and Marnila 2006, 
Table 3). 
Table 3. Selected human studies made with colostral immune preparations.
Target pathogen Effect Reference
Escherichia coli Prevention of infection Tacket et al. 1988
Escherichia coli No therapeutic effect Casswall et al. 2000
Escherichia coli
Lower incidence and shorter 
duration of diarrhea
Tawfeek et al. 2003 
Shigella flexneri Prevention of infection Tacket et al. 1992
Shigella dysenteriae No significant effect Ashraf et al. 2001
Streptococcus mutans
Reduction of S. mutans in 
dental plaque
Loimaranta et al. 
1999a, Shimazaki et 
al. 2001
Rotavirus Prevention of infection
Ebina et al. 1985, 
Davidson et al. 1989
Rotavirus
Decreased severity of diar-
rhoea
Sarker et al. 1998
Cryptosporidium par-
vum
Reduction of diarrhoea
Tzipori et al. 1987, 
Okhuysen et al. 1998
Helicobacter pylori
No eradication, decreased 
severity
Oona et al. 1997
Helicobacter pylori No eradication Casswall et al. 1998
Clostridium difficile Prevention of a relapse van Dissel et al. 2005
Oona et al. (1997) studied the effect of bovine immune whey preparation with 
specific H. pylori antibodies in treatment of H. pylori positive children.  The se-
verity of symptoms and degree of gastric inflammation decreased. The degree 
of H. pylori reduced but total eradication was not observed. These results were 
consistent with those by Casswall et al. (1998). A prophylactic effect of a co-
lostral immune preparation (IP) having specific anti- H. pylori antibodies was 20
demonstrated in a mouse model. Efficacy of the therapeutic treatment seemed 
to be related to the concentration of antibodies administered (Casswall et al. 
2002). Rotavirus infections have also been successfully prevented and treated 
with milk preparations from hyperimmunized cows (Ebina et al. 1985, David-
son et al. 1989, Sarker et al. 1998). An anti-rotavirus antibody concentrate is 
also available commercially (Rota-colostrum®). Pant et al. (2007) combined L. 
rhamnosus GG with specific bovine colostrum-derived immunoglobulins. In 
an infant mouse model this combination had a significant prophylactic effect 
against rotavirus diarrhea. 
Immune bovine colostral preparations against enterotoxigenic E. coli protected 
against infection (Tacket et al. 1988, Casswall et al. 2000). An immunoglobu-
lin enriched bovine colostrum preparation, IMMULACTM (New Zealand Dairy 
Group, Cambridge, New Zealand), containing antibodies against various bacte-
rial antigens protected mice against ETEC infection (Funatogawa et al. 2002). 
Immune bovine colostrum containing specific antibodies against S. mutans and 
S. sobrinus was capable of inhibiting the bacterial enzymes producing sticky 
capsule glycoproteins (Loimaranta et al. 1997), adherence of S. mutans cells to 
saliva-coated hydroxyapatite beads (Loimaranta et al. 1998), and augmenting 
the recognition, phagocytosis and killing of S. mutans by human leukocytes 
(Loimaranta et al. 1999b). In a short-term human study immune colostrum as a 
mouth rinse resulted in a higher resting pH in dental plaque and a lower propor-
tion of caries streptococci in plaque microbial flora (Loimaranta et al. 1999a).
16 patients suffering from Clostridium difficile diarrhea received immune whey 
protein concentrate (MucoMilk) after antibiotic treatment. In all but one case, 
C. difficile toxins disappeared from the faeces upon completion of treatment. 
During a follow-up period none of the patients suffered another episode of C. 
difficile diarrhoea (Dissel et al. 2005). The safety of this product has been de-
monstrated (Young et al. 2007).
In humans, the oral administration of bovine milk immunoglobulins is general-
ly well tolerated. Local passive immunization with bovine milk antibodies has 
the advantage of bypassing the host’s own immune system. Orally administe-
red immunoglobulins are degraded by intestinal proteases (Reilly et al. 1997) 
but IgG1 of bovine milk is quite resistant to pepsin cleavage and retains part of 
its immunological activity in the human intestine (Petschow and Talbott 1994, 
Roos et al. 1995, Warny et al. 1999). Further, pepsin cleaves IgGs to F(ab′) frag-
ments, but F(ab′) also is able to neutralize antigens.21
Selected gastrointestinal pathogens 2.3 
Helicobacter pylori 2.3.1   as a human pathogen
More than 50% of the world’s population is infected by H. pylori. The infection 
is more common in developing than developed countries. In some developing 
countries up to 80% of population is infected by the age of 20 whereas in Fin-
land the rate is less than 10% (Rautelin and Kosunen 2004). Low socioecono-
mic status, a H. pylori positive family member, high density of living, and low 
household income are associated with the infection (reviewed by Malaty 2007). 
The infection is usually acquired in childhood, and it rarely disappears sponta-
neously (Kosunen et al. 1997). Studies on the genetic diversity and geographi-
cal variation of H. pylori show that humans have carried H. pylori ever since 
they left East-Africa 58,000  3,500 years ago (Linz et al. 2007).
H. pylori infection is the most common cause of gastritis and is involved in 
peptic ulcer, gastric adenocarcinoma, and primary gastric B-cell lymphoma. 
15-20% of those colonized by H. pylori develop gastric ulcer disease, and 1% 
gastric cancer. The pathogenesis depends upon strain virulence, host genetic 
susceptibility, and environmental cofactors. 65-80% of non-cardia gastric can-
cer is associated with H. pylori (reviewed by Kusters et al. 2006). According to 
recommendations, a one-week triple therapy using a proton pump inhibitor and 
two antibiotics is used to treat H. pylori infection (Malfertheiner et al. 2007). 
After eradication the active inflammation rapidly disappears in a few weeks 
(Valle et al. 1991). Chronic inflammation can persist for months or even years 
(Veijola et al. 2007). 
H. pylori is a Gram-negative spiral shaped human pathogen. It produces urease 
enzyme, which makes the bacterium resistant to the acidic environment of sto-
mach by neutralizing the gastric acid. Through its flagella it has a good moti-
lity to move fast to the mucus layer. H. pylori also uses the gastric mucus pH 
gradient for chemotactic orientation (Schreiber et al. 2004). For the attachment 
process on the mucous cells H. pylori uses complex adhesion molecules like 
BabA (blood group antigen-binding adhesin) binding to the fucosylated Lewis 
b (Leb) histo-blood group antigen (Ilver et al. 1998), SabA (sialic acid-binding 
adhesin) binding to the sialyl Lewis x (s-Lex) glycosphingolipid (Mahdavi et al. 
2002), as well as other outer membrane proteins AlpA, AlpB, and HopZ (Peck 
et al. 1999) whose receptors are still unknown. The site of adherence is typical-
ly the intercellular junction of the epithelial cells. 
H. pylori is able to protect itself by evading host defenses (immune evasion). 
TLRs initiate the innate defence against bacteria and activate the immune cells. 
TLRs recognize bacterial LPS, yet H. pylori LPS has less inflammatory activity 
than other enteric bacteria (Birkholz et al. 1993). There is a phenotypic variati-22
on in molecular mimicry between H. pylori LPSs and human gastric epithelial 
cell surface glycoforms. Environmental factors can induce phase variation of 
polysaccharides in H. pylori that can aid adaptation of the bacterium to its eco-
logical niche (Moran et al. 2002, Bergman et al. 2004). 
H. pylori has virulence factors like cytotoxin-associated gene (cag)–pathoge-
nicity island (PAI) and the vacuolating cytotoxin (VacA) contributing to the gas-
tric diseases. CagA positive H. pylori strains are strongly associated with at-
rophic antral gastritis (Oksanen et al. 2000). After H. pylori adherence to epit-
helial cells, the type IV secretion system encoded by cag-PAI translocates the 
CagA protein into epithelial cells. Type IV secretion system is also involved in 
the induction of proinflammatory cytokines or chemokines, such as IL-8 in gas-
tric epithelial cells (Fisher et al. 2001). The presence of an intact type IV sec-
retion system allows H. pylori to colonize the gastric corpus. This results in at-
rophic corpus-dominant gastritis, thus highlighting type IV secretion system 
and CagA as major risk factors for gastric cancer development (Rieder et al. 
2005). Possibly, H. pylori lacking a cag-PAI actively suppress host cell innate 
immune responses (Guillemin et al. 2002). Genomic studies from different geo-
graphic regions have shown that cag-PAI appeared to be disrupted in the majo-
rity of patient isolates throughout the world. CagA gene was present in 72.8% 
of strains (Kauser et al. 2004).
H. pylori can be detected by invasive and/or nonivasive tests (reviewed by Lo-
gan and Walker 2001). Invasive methods require endoscopy. H. pylori can be 
detected from biopsies by histology, culture, or rapid urease test. Urease test is 
based on the pH change caused by ammonia liberated by urease enzyme of He-
licobacter. The tests contain urea and phenol red as a pH indicator. The nonin-
vasive tests include serologic testing, stool antigen test, saliva and urine tests 
and urea breath testing (UBT). In UBT the patient is given orally urea labe-
led with nonradioactive 13C or radioactive 14C. In the presense of H. pylori the 
urease metabolizes urea to produce labeled CO2 that can be measured in the pa-
tients’ breath. Detection of antibodies by serological tests is a widely used met-
hod but it cannot prove ongoing infection due to immunological memory (Kus-
ters et al. 2006). All these tests have their advantages and disadvantages, and 
there is no single gold standard in the diagnostic of H. pylori infection (Mal-
fertheiner et al. 2007).
During last decades the occurrence of H. pylori has remarkably declined in in-
dustrial countries (Kusters et al. 2006). The rate and risk of H. pylori infection 
is high in cohorts born in the beginning of the 20th century, but is much lower 
in those born later due to a decrease in the rate of H. pylori acquisition in child-
hood (Sipponen 1997). The infection is curable with antibiotic therapy, but the 
strains multiresistant to antibiotics are a growing problem worldwide (Egan et 
al. 2007). 23
Animal models and cell line studies on  2.3.2  Helico-
bacter infection
H. pylori is classified as a host specific pathogen. There are other Helicobacter 
species in different animals that do not infect humans (Fox 2002). H. felis was 
first isolated from gastric mucosa of cats (Lee et al. 1988). It has been extensive-
ly used in murine models of Helicobacter infection where it can induce gastritis, 
epithelial cell proliferation, and apoptosis (Gasbarrini et al. 2003, Kusters et al. 
2006). During the 1990s the use of a mouse-adapted H. pylori strain (SS1) that 
is able to colonize the murine stomach was described (Lee et al. 1997).
The Mongolian gerbil model is also suitable for studying H. pylori infection. In 
Mongolian gerbils, gastric inflammation is much more evident than in the mou-
se model. Mongolian gerbils tolerate infection with type I H. pylori strains and 
may develop peptic ulcer or gastric cancer (Rieder et al. 2005). Guinea pigs, pi-
glets, and nonhuman primate animals have also been used as animal models in 
studying Helicobacter infections (reviewed by Kusters et al. 2006).
Human gastric epithelial cell lines like HT29 cells, AGS cells, MKN45 cells, 
and KatoIII cells can be infected by H. pylori (Coconnier et al. 1998, Michetti 
et al. 1999, Sgouras et al. 2005, Takahashi et al. 2000, Kabir et al. 1997). They 
are commonly used to study the adhesion of H. pylori, the immune responses 
and gene expression in H. pylori infection in vitro. 
Caries streptococci 2.3.3 
Bacteria colonizing the tooth surface cause dental caries, one of the most com-
mon infectious diseases in the world. Cariogenic bacteria, mutans streptococ-
ci, consist mainly of two species, Streptococcus mutans and S. sobrinus. They 
are generally considered to be the principal ethiological agent of dental caries 
(Loesche 1986). The colonization of mutans streptococci requires the presen-
ce of hard surface and thus occurs only after tooth eruption. Cariogenic strep-
tococci adhere to tooth by interacting with the salivary pellicle, co-aggregating 
with other bacteria, or via sticky polysaccharides they synthesise. The bacte-
ria attached to tooth surface form the dental plaque. The presence of carbohyd-
rates, especially glucose and saccharose supports acid production by S. mu-
tans and results in a reduction in environmental pH, which in turn results in an 
overgrowth of mutans streptococci.
In oral cavity, saliva has a crucial role in maintaining the balance between ca-
riogenic challenges, the environment, and the host defence. Saliva contains a 
large diversity of specific and non-specific antimicrobial factors. The non-speci-
fic defence factors with anti-streptococcal potential are peroxidase, lactoferrin, 24
histatins, lysozyme, mucins, complement, agglutinins, proteins rich with proli-
ne, and carbonic anhydrase (Loimaranta 1999). Specific factors contain immu-
noglobulins, mainly IgA and IgG.
Enterotoxigenic 2.3.4   Escherichia coli in calves
Rotavirus, coronavirus, enterotoxigenic E. coli, and Crytosporidium parvum 
are the four major pathogens associated with neonatal calf diarrhoea worldwide 
(Achá et al. 2004). Nonpathogenic E. coli are part of the normal microbial flora 
of calves. Calves become infected with E. coli during or shortly after birth by 
fecal-oral transmission (Smith 1965). There are, however, types of E. coli who 
cause two common diseases of newborn calves namely coli-septicemia in sys-
temic circulation and enteric colibacillosis in the mucosal surface of the small 
intestine (reviewed by Acres 1985). Virulence factors are crucial for the proper-
ty of E. coli to cause a disease. Enterotoxigenic E. coli (ETEC) isolated from 
calves can produce heat stable toxins. Enterotoxins bind to receptor sites on the 
membrane of the intestinal epithelial cells and alter normal movement of ions 
and water across the mucosa by exerting a hormone-like effect on the entero-
cytes. The infection with ETEC thus leads to acute diarrhoea culminating in 
dehydration, metabolic acidosis, and death in severe cases (Acres 1985). ETEC 
contain pili or fimbriae, which allow them to colonize the small intestine by at-
taching to the epithelial cells. The most common fimbriae observed on ETEC 
from calves with diarrhea are F5, also named K99, and F41 (Achá et al. 2004). 
ETEC causes diarrhoea mainly during the first days of life. Colostrum provi-
des protection against diarrhoea if consumed before the infection occurs. Besi-
des immunoglobulins nonspecific factors like lactoferrin, transferrin, and lac-
toperoxidase system are crucial for prevention of ETEC-infection (Acres 1985). 
Lactoferrin and transferrin have bacteriostatic effects against E. coli due to their 
ability to bind iron, which is essential for bacterial growth (Bullen et al. 1972). 
Milk also contains glycoconjugates, which have been suggested to serve as li-
gands for bacterial fimbriae and thus prevent the bacterial attachment to mu-
cosa. However, the adhesion of ETEC to colostral gangliosides was considerab-
ly weaker than that to gangliosides from the milk (Martin et al. 2003).
Lactic acid bacteria as antimicrobial agents 2.4 
Intestinal microbiota  2.4.1 
The intestine is the largest immune organ of the body and it is metabolically 
the most active organ in humans. It provides a protective barrier against inco-
ming bacteria (Ouwehand 2007). The human large intestine contains more than 25
800 different bacterial species (Bäckhed et al. 2005, Ouwehand 2007). The in-
testinal microflora is the major driving force in maturation of the immune sys-
tem after birth (Grönlund et al. 2000, Kalliomäki et al. 2001). Its composition 
is mainly formed during birth and from the diet of the first month of life, but 
modifications in some aspects of cellular immunity can be achieved even in the 
elderly by a supplementation with an immunostimulating probiotic (Gill et al. 
2001). In gastric contents the levels of bacteria are usually below 103 cfu/g due 
to the acidic environment. In small intestine the bacterial numbers range from 
104 to 107 cfu/g and in large intestine typically up to 1012 cfu/g (for review, see 
Salminen et al. 1998).
Probiotic bacteria  2.4.2 
Fermenting is a traditional food processing technology known for thousands of 
years. Lactic acid bacteria (LAB) have a dominant role in the fermentation of 
dairy products, meat, and vegetables to improve their aroma and texture, and 
to prevent spoilage (Caplice and Fitzgerald 1999). 
Probiotics have been defined as live microbial feed supplements that have be-
neficial effects on the host by improving its intestinal microbial balance (Fuller 
1989), or as live microorganisms that, when administered in adequate amounts, 
confer a health benefit on the host (FAO/WHO 2002). A majority of probiotic 
bacteria belong to the families of lactobacilli or bifidobacteria. To benefit hu-
man health a probiotic must have good technological properties, it must survi-
ve through upper gastrointestinal tract, and it must be able to function in gut 
environment (Mattila-Sandholm et al. 2002). In commercial dairy products the 
concentration of probiotics is usually in the range of 108-109cfu/ml. The safe-
ty of probiotics is of prime importance. The safety aspects include the human 
origin, non-pathogenicity, and antibiotic resistance specifications of the strain 
(Saarela et al. 2000). 
The promotion of the host defence systems, modulation of the immune system 
as well as the competitive exclusion of harmful microbes are thought to be key 
elements for the mechanisms by which probiotics exert their health effects (for 
review, see Saxelin et al. 2005). The probiotics are suggested to normalize the 
intestinal microbiota, have metabolic effects, and immunomodulation potential 
(Parvez et al. 2006). The probiotic strains differ in their characteristics, and it is 
therefore likely that selected mechanisms are also strain-specific. Various health 
benefits from consumption of probiotics are summarized in Table 4. 
Some probiotic bacteria interact with immune cells in the mucosa. They can 
modulate cytokine and chemokine release, and regulate the immune responses 
in the intestinal mucosa (Isolauri 2001). For example, consumption of Bifido-
bacterium lactis HN019 enhanced the proportions of T cells in the peripheral 26
circulation, leukocyte phagocytosis, and tumoricidal activity (Gill et al. 2001). 
Lactobacillus rhamnosus GG (LGG) has been extensively studied for its health 
promoting effects in humans and animals. These benefits include prevention of 
diarrhea, allergy, alcohol induced liver disease, and colon cancer, reduction of 
caries risk, and an application as the adjuvant for vaccines (Goldin 1998, Näse 
et al. 2001, Kalliomäki et al. 2007).
Table 4. Suggested health effects of probiotics (Data from Parvez et al. 2006).
Effect on human health
Strengthening of innate immunity
Alleviating food allergy symptoms in infants
Controlling inflammatory bowel diseases
Lowering serum cholesterol
Improving lactose tolerance
Reducing risk factors for colon cancer
Controlling irritable bowel syndrome
Suppressing endogenous pathogens, e.g. antibiotic-associated diarrhoea
Suppressing exogenous pathogens, e.g. travellers diarrhoea
LAB against  2.4.3  H. pylori 
The in vitro inhibition effect of many LAB is associated with lactic acid (Mido-
lo et al. 1995, Aiba et al. 1998). Lactic acid inhibits the urease system of H. py-
lori (Sgouras et al. 2004). Bacterial culture supernatants also exhibit anti-Heli-
cobacter effect independent of lactic acid. The culture supernatants of strains 
of L. acidophilus, Clostridium butyricum, Bacillus subtilis, Weissella confusa 
and Enterococcus faecium inhibited the growth of H. pylori even in neutral pH 
(Coconnier et al. 1998, Michetti et al. 1999, Takahashi et al. 2000, Pinchuk et 
al. 2001, Kang et al. 2005, Nam et al. 2002, Tsai et al. 2004). The bactericidal 
effect of L. acidophilus CRL 639 was related to compound released after lysis 
(Lorca 2001).  Lacticin A164 produced by Lactococcus lactis subsp. lactis was 
effective against H. pylori probably by accelerating cell lysis (Kim et al. 2003). 
Viable L. casei and strains of L. acidophilus, B. longum, B. lactis, LGG, L. plan-
tarum 299v, L. gasseri OLL2716 (LG21), and L. paracasei have shown inhibi-
tory activity against H. pylori growth in vitro (Cats et al. 2003, Sgouras et al. 
2004, Wang et al. 2004, Vilaichone et al. 2002, Chatterjee et al. 2003, Hütt et 
al. 2006, Ushiyama et al. 2003). 
W. confusa PL9001, C. butyricum and L. salivarius inhibited H. pylori at-
tachment in MKN45 cells likely mechanism being nonspecific steric hindran-27
ce, maybe partially extracellular secretory product (Kabir et al. 1997, Takahashi 
et al. 2000, Nam et al. 2002). The spent culture supernatants of L. acidophi-
lus LB and E. faecium decreased the adhesion of H. pylori on human cells (Co-
connier et al. 1998, Tsai et al. 2004). Selected L. reuteri strains inhibited the 
binding of H. pylori to specific glycolipid receptors asialo-GM1 and sulfatide. 
Strains from intestine or feces but not from fermented molasses exhibited bin-
ding to the glycolipids. It was suggested that the glycolipid-binding protein is 
associated with cell surface (Mukai et al. 2002). 
Some probiotic LAB reduce the severity of inflammation in Helicobacter in-
fection (Aiba et al. 1998, Sakamoto et al. 2001, Sgouras et al. 2005). IL-8 sec-
retion by AGS and MKN45 cells was reduced with L. salivarius, LG21, and L. 
johnsonii La1 spent culture supernatant, but the supernatant did not affect H. 
pylori viability. Suggested mechanism is reducing proinflammatory chemotac-
tic signals responsible for the recruitment of lymphocytes and neutrophils in 
the lamina propia (Kabir et al. 1997, Ushiyama et al. 2003, Sgouras et al. 2005, 
Tamura et al. 2006). 
LG21, L. casei strain Shirota, and L. salivarius decreased the number of H. pylo-
ri in infected mice (Ushiyama et al. 2003, Sgouras et al. 2004, Aiba et al. 1998). 
Cure of persistent infection with H. pylori in mice was demonstrated following 
infection with C. butyricum (Takahashi et al. 2000). Oral treatment with L. aci-
dophilus LB-supernatant protected conventional mice against H. felis –infec-
tion but did not eradicate an existing Helicobacter infection (Coconnier et al. 
1998). L. salivarius prevented H. pylori infection in gnotobiotic BALB/c mice 
and eliminated colonization by H. pylori (Kabir et al. 1997). H. pylori coloni-
zation and inflammation but not apoptosis were reduced in mice treated with 
live L. rhamnosus R0011 and L. acidophilus R0052 (Lactofil) in drinking wa-
ter prior to H. pylori SS1 infection. The mechanism was attributed to bacterici-
dal effects (Johnson-Henry et al. 2004). 
The effect of L. johnsonii La1 on H. pylori infection as such or in combination 
with antibiotic treatment has been carried out in a number of double blind, ran-
domized, controlled clinical trials. According to values of urea breath tests the 
number of H. pylori was reduced following treatment with La1 suggesting that 
regular intake of La1 contribute to restrict the size of the population of H. pylori, 
and may delay colonization (Michetti et al. 1999, Felley et al. 2001, Cruchet et 
al. 2003, Gotteland et al. 2003, Pantoflickova et al. 2003). Inflammation and the 
severity of gastritis also decreased during treatment. It was suggested that La1 
could adhere in the stomach and act through a direct bacterial interference, se-
crete anti-bacterial substances, or to modify immunological response of the host 
(Felley et al. 2001). Triple therapy supplemented with a fermented milk prod-
uct containing L. casei DN-114 001 (Actimel) enhanced the therapeutic benefit 
in a randomized double blind controlled study (Sykora et al. 2005). In other hu-28
man studies a treatment with Saccharomyces boulardii, L. brevis, L. acidophi-
lus, LG21, B. lactis, or L. casei had a suppressive effect on H. pylori coloniza-
tion (Gotteland et al. 2005, Linsalata et al. 2004, Mrda et al. 1998, Canducci et 
al. 2000, Sakamoto et al. 2001, Cats et al. 2003, Wang et al. 2004). A strong in-
hibitory activity against H. pylori in vitro does, however, not guarantee a sup-
pressive effect in vivo (Wendakoon et al. 2002). Negative results from clinical 
trials have been reported also by Shimizu et al. (2002), Opekun et al. (2005), 
and Goldman et al. (2006).
As seen in clinical studies, a regular intake of probiotics does not eradicate H. 
pylori. However, it contributes to maintaining lower concentrations of H. pylori 
in a H. pylori positive at-risk population (Gotteland et al. 2005). Further, many 
studies report on the reduced side effects and increased tolerability during treat-
ment with triple therapy by a supplementation of LGG, S. boulardi, Lactoba-
cillus spp. & bifidobacteria, L. reuteri ATCC 55730, L. rhamnosus LC705 and 
Propionibacterium freudenreichii ssp. shermanii JS, L. casei subsp. casei DG,   
and C. butyricum MIYAIRI 588 (Lykova et al. 1999, Armuzzi et al. 2001a, b, 
Cremonini et al. 2002, Tursi et al. 2004, Myllyluoma et al. 2005, Shimbo et al. 
2005, Lionetti et al. 2006).
LAB against  2.4.4  S. mutans
The literature concerning probiotic bacteria and oral health is still scarce (Twet-
man and Stecksén-Blicks 2008). The oral cavity becomes colonized by various 
species of indigenous microflora during the first year of life. Some probiotic 
bacteria can be found from mouth during and some weeks after an intervention 
but a permanent colonization does not take place in an established microflora of 
adults (Meurmann et al. 1994, Busscher et al. 1999, Yli-Knuuttila et al. 2006, 
Krasse et al. 2006). LAB with probiotic properties can, however, be found in 
the oral cavity (Meurman and Stamatova 2007). Haukioja et al. (2006) tested 
the colonization potential of a number of LAB strains and found that lactoba-
cilli showed better adherence than bifidobacteria to oral surfaces.
The treatments with probiotic bacteria have shown beneficial effects on oral 
microflora by reducing the number of S. mutans (Table 5). LGG, L. casei, and 
L. reuteri have shown a potential to reduce the risk of caries (Meurman et al. 
1994, Näse et al. 2001, Ahola et al. 2002, Busscher et al. 1999, Nikawa et al. 
2004). Also consumption of Bifidobacterium DN-173 010 resulted in a reducti-
on in salivary mutans streptococci (Caglar et al. 2005). Further, probiotic bac-
teria can be effective in controlling other oral pathogens like yeasts (Hatakka 
et al. 2007). More studies are, however, needed to confirm the role of probiotics 
in oral cavity (Meurman and Stamatova 2007).29
Table 5. Controlled clinical intervention studies on the effect of probiotic bacte-
ria on the salivary levels of mutans streptococci (Data from Twetman and Steck-
sén-Blicks 2008). 
Probiotic
Effect on mutans 
streptococci
Reference
L. rhamnosus GG Decreased counts 
Näse et al. 2001, Ahola et al. 
2002
L. reuteri Decreased counts 
Nikawa et al. 2004, Caglar 
et al. 2006
Lactobacillus spp. No change in counts  Montalto et al. 2004
Bifidobacteria Decreased counts  Caglar et al. 200530
Aims of the study 3 
The aim of the present study was to investigate the effects of bovine colostrum, 
specific colostral antibodies, and some lactic acid bacteria on gastrointestinal 
infections; especially Helicobacter pylori induced gastritis and dental caries. 
The effect of colostrum on the activity of the complement system in neonatal 
calves was also studied.
The specific aims of the study were
To evaluate the effect of a commercial immunoglobulin concentrate made  • 
from pooled colostral whey on the complement-mediated bacteriolytic and 
opsonisation activities in the sera of neonatal calves.
To investigate the effectiveness of a bovine colostral control preparation and  • 
IP containing specific antibodies against H. felis in the prevention and tre-
atment of H. felis infection in mice, and to test the efficacy of a combined 
treatment with specific antibodies and amoxicillin on H. felis infection.
To investigate whether IP antibodies remain active when stored in UHT  • 
-treated or in fermented milk, and whether there is an inhibitory, additive 
or synergistic effect with LGG in preventing the adherence of S. mutans to 
saliva-coated hydroxyapatite.
To test and locate the  •  in vitro anti-Helicobacter activity of strains belong-
ing to Lactobacillus plantarum group.
To study the adhesion of  •  H. pylori pretreated with LAB and colostral prep-
arations in an AGS cell model and to investigate the effect of LAB and co-
lostral preparations on IL-8 production by H. pylori infected AGS cells.31
Materials and methods 4 
Bacterial strains, cell lines and culture condi- 4.1 
tions
The bacterial strains used in this study are listed in Table 6. Detailed desc-
riptions of cultivation media and culture conditions are presented in studies 
(I-V).
Table 6. The bacterial strains used in the study.
Strain Source Study
E. coli strain IH3080 University of Helsinki, Finland I
E. coli strain JM103 with plas-
mid pCSS962/pGB3
Lampinen et al. 1992, University 
of Turku, Finland.
I
H. felis strain CS1 II
H. pylori strain NCTC11637 University of Helsinki, Finland II, IV-V
Lactococcus lactis MG1363 Gasson 1983 V
L. paraplantarum DSM 10641 IV
L. paraplantarum DSM 10667 IV
L. paraplantarum DSM 14485 Curk et al. 1996 IV
L. pentosus Vege-Start 60 
Chr. Hansen A/S, Copenhagen, 
Denmark
IV
L. plantarum DSM 20174 
(ATCC 14917) 
IV
L. plantarum MLBPL1 isolated from sauerkraut by MTT IV, V
L. plantarum Vege-Start 60 
Chr. Hansen A/S, Copenhagen, 
Denmark
IV
Lactobacillus rhamnosus GG 
(LGG) 
ATCC 53103 II, V
S. mutans ATCC 25175 (sero-
type c)
III
 
Human AGS-cells (CRL-1739) from American Type Culture Collection (Ma-
nassas, VA) were cultured in RPMI 1640 medium + GlutaMAX 1 (Invitrogen, 
Paisley, UK) supplemented with 10% heat-inactivated fetal bovine serum (FBS) 
(Biochrom AG, Berlin, Germany) in a 5% CO2 atmosphere at 37°C. For the as-
says described here, cell suspension was placed in each well of a flat-bottom 
96-well CellBind plate (Corning Inc., Corning, NY, USA), and the plate was in-
cubated at 37°C under 5% CO2 atmosphere for 2-3 days.32
Fractions from  4.1.1  L. plantarum MLBPL1 cultures 
(IV)
Lactobacilli were cultivated in MRS broth (de Man et al. 1960). Cell-free cultu-
re supernatants from LAB were obtained by centrifugation. A whole cell lysa-
te of L. plantarum MLBPL1 was obtained by mixing harvested cells with glass 
beads, and homogenizing by vigorous shaking. Cell wall fragments and intra-
cellular fraction were separated from the whole cell lysate by centrifugation.
The cell-free culture supernatant of L. plantarum MLBPL1 was filtered to ob-
tain fractions <3, >3, <10, and >10 kDa. The pH of the culture supernatant was 
adjusted to 6.3. The supernatant fluid was then precipitated with ammonium 
sulphate. The precipitate was collected by centrifugation and dissolved into 10 
mmol/1 phosphate buffer, pH 7.0. Samples of the crude and precipitated cultu-
re supernatant were incubated at 100°C for 10 min.
Samples of L. plantarum MLBPL1 cell-free culture supernatant, precipitated 
with ammonium sulphate, were treated with α-amylase, pepsin, proteinase K, 
N-glycosidase F, or neuraminidase. The anti- Helicobacter activity of the pre-
parates obtained was tested by measuring inhibition zones on Brucella agar pla-
te as described later.
Colostral immune preparations  4.2 
Production of colostral preparations (II, III, V) 4.2.1 
The immunization protocol was approved by the Animal Care Committee of 
MTT Agrifood Research Finland. Pregnant Friesian cows were injected intra-
muscularly on both sides of the neck with vaccine consisting of 10% (v/v) inacti-
vated bacterial suspension with Al(OH)3 as adjuvant. Immunization was started 
at the onset of drying off about 2 months before the predicted day of parturiti-
on. Four booster injections were given at 1-week intervals starting 2 weeks from 
the initial injection. The cows were healthy and did not receive any antibiotics 
during the immunization. The first five milkings after calvings were collected 
and frozen immediately. The calves were fed with colostrum from other cows 
of the same herd.
The process for colostral preparations is presented in Figure 3. Colostra were 
thawed, pooled, and then heated to +37°C. Fat was removed with a separator, 
casein was coagulated with chymosin, and lactose was hydrolysed with lactase 
enzyme. Coagulated casein was removed with cheese pressing equipment. Su-
gars and salts were removed from the whey by chromatographic and membra-
ne-filtering techniques, as described by Loimaranta et al. (1997). The protein 33
concentrate obtained was sterilized by microfiltration and lyophilised at -45°C 
to obtain immune preparation (IP). A control preparation (CP) was made simi-
larly from colostra of non-immunized cows. 
The total protein content of the preparations was determined by the Kjeldahl 
method. The IgG content was measured by a chromatographic method as desc-
ribed by Syväoja and Korhonen (1994). Concentrations of IgA and IgM were 
assessed with RID kits, and IGF-1, TGF-β1, and TGF-β2 by enzyme-linked im-
mune sorbent assay (ELISA) methods. 
To inactivate the complement system, samples of IP and CP were incubated at 
56°C for 30 minutes. To remove the small molecular weight components and 
to further enrich the antibody fraction of IP, the powder was dissolved in water 
and filtered through a 100 kD membrane and lyophilised.
Figure 3. Production of bovine colostral immune preparations with specific an-
tibodies (IP).
 Stability of IP and LGG in milk (III) 4.2.2 
The ability of bovine antibodies to retain their activity was tested by storing 
them in a commercial UHT treated milk-based drink for toddlers (Muksu-Milk, 
Valio Ltd, Turenki, Finland). 5 ml of sterile 15% (w/v) solution of caries IP was 
injected into the carton to obtain a final concentration of 0.375%. Injected car-
tons and uninjected control cartons were incubated in triplicate at three diffe-
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rent temperatures: 5°C, 21°C, and 30°C. The antibody concentrations and the 
ability of antibody-supplemented Muksu-Milk to inhibit the adherence of S. mu-
tans cells to salivacoated hydroxyapatite were measured, as described below, at 
the beginning of the test and after storage for 1 and 2 months. 
Fresh cow’s milk, supplemented with IP was fermented with LGG and stored 
for 7 weeks in order to evaluate the possible effects of fermentation and stora-
ge of antibodies together with LAB on antibody titres and functions (Figure 4). 
Fresh milk was first centrifuged to remove fat, large casein particles, bacteria,   
and somatic cells. IP and CP were mixed with pasteurized milk to obtain a fi-
nal IP concentration of 5% (w/v). After LGG inoculation the milk samples were 
incubated at 37°C for 48h, and stored at 4°C. To assess the effect of low pH on 
antibodies and LGG, both IP milk and non-IP milk were also fermented in 50 
mM HEPES buffer to maintain pH 7 during fermentation and storage. pH, lac-
tic acid content, and number of viable cells were determined during the fermen-
tation and storage periods. Aliquots of IP containing samples were analysed for 
antibody titres by ELISA. 
Figure 4. Study design for the fermentation of the anti-caries immune prepara-
tion (IP) or the control preparation (CP) with L. rhamnosus GG (LGG) (107 cfu/
ml).
Analytical methods 4.3 
Determination of specific antibodies (I, II, III) 4.3.1 
Specific antibodies in bovine colostrum, milk, and serum samples were me-
asured by ELISA. Briefly, microtitre plates were coated with the antigen. After 
Fresh milk 
centrifugation, pasteurisation 
milk + 
LGG + 
5% CP 
milk + 
LGG + 
5% IP 
milk + LGG 
milk + 
5% IP 
milk + LGG 
+ HEPES 
milk + LGG 
+ 5% IP + 
HEPES 
Fermentation for 48 h at 37°C 
Storage for 50 days 
Determination of antibody titres, inhibition of adhesion, viability of 
LGG, pH and concentration of lactic acid 
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overnight incubation at 4°C, the wells were washed with PBS containing 0.05% 
Tween 20 (PBST) and rinsed three times with deionized water. Diluted samp-
les were added to the antigen-coated plates. After 90 min incubation at 37°C 
the wells were washed as above and a secondary anti-bovine IgG or anti-mou-
se IgG antibody with alkaline phosphatase conjugate was added for 90 min at 
37°C. After washing, the plates were developed with p-nitrophenylphosphate 
disodium salt in diethanolamine-MgCl2 buffer, pH 10.0. The absorbance va-
lues at 405 nm were recorded with a Multiskan MCC/340 spectrophotometer 
(Thermo Labsystems, Vantaa, Finland). Endpoint titres of specific antibodies 
were determined at a cut-off level of 0.5 from OD405. 
I 4.3.2  n vitro H. pylori growth inhibitory activity (II, 
IV)
The bactericidal activity of colostral preparations was measured by a plate-
counting method, as described by Korhonen et al. (1995). Briefly, a sample 
containing 2x107 bacteria/ml was prepared by mixing H. pylori suspension, 
sample (IP, CP, and heated preparations), and 5% FBS with or without active 
complement. The test samples were incubated under microaerophilic condi-
tions at 37°C for 2 hours. After that, 10-fold dilutions (from 10-2 to 10-8) were 
made from samples, and cultured on Brucella agar plates. Colony forming 
units (cfu) were counted.
Inhibition of the growth of H. pylori by LAB culture supernatants and cellu-
lar fractions obtained as described above was screened as in Wendakoon et al. 
(1998). Briefly, H. pylori suspension containing ca. 108 bacteria was spread on 
Brucella agar plates. Wells were cut with a sterile straw and filled with a LAB 
sample. Amoxicillin trihydricum (Orion Diagnostica, Espoo, Finland) in con-
centrations of 0.2–1 mg /1 was used as a positive control, and MRS broth as 
a negative control. Plates were incubated at 37°C under microaerophilic con-
ditions for 3 days, after which the diameters of the inhibitory zones were me-
asured.
Infection studies with AGS cells (V) 4.3.3 
H. pylori bacteria were harvested from 1-2 days solid cultures and resuspended 
into PBS to a concentration of ca. 109–1010 cfu/ml. Cells of the grown LAB cul-
tures were counted in Bürker’s chamber, and the concentration of cultures was 
adjusted to 1010 cfu/ml with PBS. Samples of the grown LAB cultures were 
inactivated by heating at 80°C for 20 min. Before infection of AGS cells on 
microtitre plates, H. pylori were pretreated with different concentrations of CP, 
IP, or LAB for 40 minutes at 37°C. An AGS cell-to-bacteria ratio of 1:40 was 
used in the infection. Adhesion test was carried out as described by Shmuely 36
et al. (2004). After 2 hours infection AGS cells were washed with PBS. Urease 
test was performed by adding 100 µl of urease test solution (7 mM phosphate 
buffer pH 6.8, 110 mM urea, 10 mg/l phenol red) into each well of the microtit-
re plate. After a reaction time of 10-30 min, absorbance values at 540 nm were 
recorded with a Multiscan MCC spectrophotometer. The relative adhesion le-
vel was calculated by dividing the absorbance value of the sample with the ab-
sorbance value of PBS control containing the same amount of H. pylori. 
For the determination of IL-8, the culture media of AGS cells were collected 
after 20 h infection, centrifuged, and kept at −20°C until assayed for IL-8. IL-8 
levels were determined by ELISA (Bender Medsystems, Vienna, Austria) ac-
cording to the manufacturer’s protocol. Absorbance values at 450 nm were me-
asured with a Multiscan MCC spectrophotometer. 
Adherence to hydroxyapatite (III) 4.3.4 
The effect of pretreatment with fermented IP and UHT milk samples on the ad-
herence of mutans streptococci to hydroxyapatite was studied as described in 
Loimaranta et al. (1998). Briefly, rehydrated spheroidal hydroxyapatite beads 
(BDH Chemicals Ltd, Poole, UK) were treated for 60 min with human parotid 
saliva diluted 1:2 with adhesion buffer (1.0 mM potassium phosphate, 50 mM 
KCl, 1.0 mM CaCl2 and 0.1 mM MgCl2, pH 6.5). Uncoated sites were blocked 
with 0.5% human albumin (Sigma). Saliva-coated beads were treated with the 
sample before the addition of S. mutans labelled with L-[35S]methionine (NEN 
Research Products, Du Pont, France). Unbound bacteria were removed by wa-
shing with the adhesion buffer and the bound activity was measured by liquid 
scintillation counter (Microbeta, Wallac, Finland).
Measurement  of  complement-dependent  4.3.5  E. 
coli bacteriolytic activity (I)
The serum samples of newborn calves were from a previous experiment car-
ried out by Nousiainen et al. (1994). Briefly, twenty-one calves were divided 
into three groups, and given one of three feeding regimens on the first day of 
life. The control group was fed normal pooled whole milk and pooled colostrum 
with total immunoglobulin intake 19.5 g. The Treat1 and Treat2 groups were 
fed normal pooled whole milk, pooled colostrum, and an immunoglobulin con-
centrate giving a total immunoglobulin intake of 52.7 and 119.0 g, respectively. 
From day 2 the calves were fed similarly. Blood samples were drawn on days 2, 
7, 14, and 30 after birth. The sera were stored at -20°C for analysis.
Bacteriolytic activity was measured by a method modified from that descri-
bed by Virta et al. (1995, 1998). The assay is based on a complement-sensitive 37
nonencapsulated E. coli strain JM103 containing a luciferase structural gene. 
In the presence of luciferine, luciferase converts the chemical energy asso-
ciated with ATP into green light, which can be measured with a luminometer. 
Thus, the amount of light emitted is proportional to the number of metaboli-
cally active cells (Griffiths 1996). The survival of bacteria in the serum samp-
les was calculated relative to that in heat-inactivated (56°C, 30 min) FBS. The 
results were determined as a serum dilution with a chemiluminescence emis-
sion 50% of that of blank samples containing a dilution buffer instead of a se-
rum sample. This dilution represents a lethal dose 50% value (LD50) for the 
serum sample.
The serum samples were thawed and diluted serially with Hank’s balanced salt 
solution (HBSS) containing heat-inactivated FBS. Samples in duplicates were 
incubated with 3.6x106 cells of E. coli JM103 in microtitre plate wells for 90 
min at 37°C. After that, 0.25 mM D-luciferine (Bio-Orbit, Turku, Finland) in 
0.1 M disodiumcitrate (pH 5.0) was added and the bioluminescence emission 
was measured for 1 hour with a Luminoskan EL1 luminometer (Labsystems, 
Helsinki, Finland). 
The alternative pathway of complement was analysed by blocking the classi-
cal pathway with 10 mM EGTA in Ca
2+
- and Mg
2+
-free HBSS. The inactiva-
tion of E. coli was measured as described above.
Opsonisation and phagocyte activation (I) 4.3.6 
A complement-insensitive E. coli strain IH3080 was used as a model for se-
rum opsonisation activity against bacteria. A mixture in HBSS containing 
1% of serum sample from calves and 2 x 109 E. coli was shaken for 35 minu-
tes at 37°C. After centrifugation, the pellet was suspended in HBSS and sto-
red at -20°C. The control samples contained heat-inactivated FBS instead of 
serum samples. 
The phagocyte oxidative burst activity was measured as luminol (5-amino-
2,3-dihydro-1,4-phthalazinedione, Sigma) enhanced chemiluminescence (CL) 
emission. The reaction mixture consisted of 2.5 x 104 leukocytes isolated from 
the blood of a healthy calf as described by Robinson (1993), and 0.4 mM lu-
minol in 0.1% gelatin-HBSS. The CL reaction was stimulated with E. coli cells 
opsonised either with heat-inactivated FBS or with the serum samples (2.5 x 
106 cells/well). The CL response was measured in four replicates at 90 s inter-
vals for 1 hour at 37°C with a luminometer. The opsonisation capacities are 
expressed as the relative increase in the oxidative burst activity of the phago-
cytising leukocytes evoked by opsonised E. coli as compared to that of nonop-
sonised E. coli.38
C3 content (I) 4.3.7 
The relative content of the complement C3 component in the sera was estima-
ted by the radial immune diffusion method. In brief, anti-bovine C3 serum 
(Cappel, Organon Teknika, Durham, NC, USA) was diluted 1:80 in 2% Sea-
Kem LE agarose in Mancini buffer and poured on petri dishes. After cutting 
wells with a diameter of 3 mm, serum sample was applied to each well. Af-
ter 72 h incubation at +4oC in a humid chamber, the precipitation rings were 
stained with PhastGel Blue R (Pharmacia LKB Biotechnology, Uppsala, Swe-
den) and the diameter of the precipitant was measured. FBS was used as a 
standard.
Infecting mice with  4.4  H. felis (II)
The protocols for the infection and treatment of the mice were approved by the 
local Animal Care and Ethics Committee. Balb/c mice were obtained from the 
Laboratory Animal Centre of the University of Helsinki, and SJL mice from 
the Laboratory Animal Centre of the University of Turku. H. felis CS1 was cul-
tured on Brucella agar as described above, and suspended in PBS. The mice 
were infected on three consecutive days by oral administration of 0.1 ml PBS 
containing 10
8
 cells of H. felis. Uninfected mice were used as healthy controls. 
The mice were maintained in conventional conditions and allowed free access 
to non-sterile food and water. 
The H. felis status of infected mice was assessed by bacteriological stainings 
(Gram and acridine orange stains), gastric histology (Giemsa and hematoxy-
lin-eosin stains), and by measurement of anti- H. felis antibodies in sera by the 
ELISA method. 
Treatment of gastritis in mice (II) 4.4.1 
The efficacy of IP, CP, complement, and amoxicillin against murine H. felis 
infection was tested in three consecutive trials (Figure 5, II). 10 + 17 mice ser-
ved as infected controls.  In the preliminary experiments, the amoxicillin tri-
hydricum (Orion Diagnostica, Espoo, Finland) dosage of 40 µg/g for 6 days 
was shown to eradicate H. felis from some but not all of the animals (data not 
shown). Thus, it was assumed that this was a proper dosage to test the com-
bined effect of IP and amoxicillin treatments. In trial 1 the mice were killed 
4-5 weeks after the end of the treatment. Since no eradication but only a lowe-
red level of colonization was expected the mice were killed immediately af-
ter the treatment in trials 2 and 3 in order to prevent reinfections or spread of 
H. felis. 39
 
Figure 5. Study design for treating H. felis infected mice with colostral immu-
ne preparation (IP) containing specific antibodies against H. felis, control pre-
paration (CP), complement source (NBS, normal bovine serum), complement 
inactivated IP and CP, concentrated IP (IgG of IP), or amoxicillin. Infected and 
uninfected mice without treatment were used as infected and healthy controls. 
The time between infection and treatment was 1 week in trial 1, and 2 months 
in trials 2 and 3. 
Preventing infection with immune and control  4.4.2 
preparation (II)
The prophylactic efficacies of IP containing specific antibodies against H. felis, 
and CP were studied by giving Balb/c mice IP or CP orally. The administrati-
on of colostral preparations started two days before, and ended five days after 
the H. felis administration. Infected controls received phosphate buffered sali-
ne (PBS) instead of IP or CP. Uninfected mice served as healthy controls. The 
mice were killed from seven to eight weeks after the H. felis inoculation. Blood 
samples were taken from the orbital venous plexus and the stomachs were dis-
sected and prepared for the assessment of H. felis status, colonization and in-
flammation.
Statistical analyses 4.5 
Data concerning infection status of mice were analysed with exact chi-square 
test. The results for the inhibition of adhesion of S. mutans to hydroxyapatite 
particles were analysed with Wilcoxon’s non-parametric sign test. For calves, 
the covariance structure of the repeated measurements was chosen by compa-
ring several potential structures using Akaike’s information criterion (Wolfin-
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ger 1996). Data concerning the adhesion of H. pylori and IL-8 production by 
AGS cells were analysed using analysis of variance for randomised complete 
block design by considering each replicate as a blocking factor and the combi-
nation of the sample, its activity level, and concentration as a treatment factor. 
Pairwise comparisons were performed using two-sided t-type tests. The para-
meters of the models were estimated by the restricted maximum likelihood es-
timation method and degrees of freedom were calculated using the Kenward-
Roger method (1997). The data were analyzed using SAS Statistical software 
for Windows releases 6.12, 8.01, and 9.1.3 and SAS Enterprise Guide release 4.1 
(SAS Institute Inc., Cary, NC, USA).41
Results 5 
Composition and stability of colostral prepara- 5.1 
tions (II, III, V)
Cows tolerated the immunization process well, and no severe side effects were 
observed. Before immunization, the levels of specific antibodies in the sera of 
the cows were negligible. The immunization protocol resulted in the develop-
ment of a specific antibody response in all cows (Figure 6). Typical composi-
tions of colostral preparations are presented in Table 7.
Figure 6. Typical titres of H. felis specific IgG antibodies in the serum (a) and in 
the three first milkings after calving (b) of an immunized cow.
IP did not contain any cross-reactive antibodies against LGG, whereas speci-
fic activities towards S. mutans, H. pylori, and H. felis of respective IPs were 
high. The antibody titre for H. pylori -specific IgG were still on a high level af-
ter 10 years storage at -20°C. The concentrations of anti-caries IgG antibodies 
of IP remained unchanged during storage at 5°C, 21°C, and 30°C for 2 months 
in UHT milk drink. The presence of live LGG or HEPES had no significant ef-
fect on IP antibodies during the 50-day storage at 4°C. However, during this 
long storage period, there was a steady decline in titres from 10 days after the 
beginning of storage, and after 50 days about 30% of the original activity was 
left. During the 50 days storage at 4°C, IP did not have any notable effect on 
the growth of LGG. 
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Table 7. Major composition of colostral preparations. N= number of preparati-
ons analyzed.
n Immune preparation Control preparation
protein 3 68-90% (w/w) 71-91% (w/w)
IgG 3 42-52% (w/w) 44-52% (w/w)
IgA 1 7% (w/w) 3.2% (w/w)
IgM 1 4.3% (w/w) 4.9% (w/w)
IGF-1 1 1.2 mg/g 0.22 mg/g
TGF-β1 1 0.11 mg/g 0.13 mg/g
TGF-β2 1 1.5 mg/g 1.3 mg/g
Dependence of the bactericidal activity of co- 5.2 
lostral preparations on the presence of active 
complement (II) 
In vitro, both CP and IP were bactericidal against H. pylori. Colostral prepara-
tions reduced the H. pylori cfu by two orders of magnitude from 107 to 105. Si-
milar incubation with normal bovine serum and colostral preparations supple-
mented with serum killed all the H. pylori in the samples. The bactericidal ac-
tivity was solely dependent on the presence of active complement in the solu-
tions. When the preparations were heated to 56°C for 30 min, no bactericidal 
activity was detected. The bactericidal activity was restored by the addition of 
a complement source (FBS).
Substantial increase of the complement activi- 5.3 
ties of serum by feeding colostral whey con-
centrate to neonatal calves (I)
Two groups of neonatal calves were fed different amounts of immunoglobulin 
concentrate for the first two feedings. The sera of both immunoglobulin concent-
rate groups had 2-3 times higher bacteriolytic activity than the control group of 
both the classic (P<0.005) and alternative (P<0.0005) pathways of complement 
at days 2 and 7 after birth (Figure 7). At day 30 there were no differences bet-
ween the groups except, in the Treat2 group, where the activity of the classic pat-
hway was still higher at day 30 than in the controls (P=0.03). No differences in 
the complement component C3 contents between the groups were observed. 43
The C3 levels increased significantly in all groups during the study (P<0.0001). 
In both immunoglobulin concentrate treated groups the initial E. coli JM103-
specific antibody levels were high and decreased towards the control values in 
the course of time. 
The group fed highest amount immunoglobulins had the highest serum E. coli 
IH3080 opsonisation capacity. At day 30, the capacities of the control group 
had risen to the same level as those of the immunoglobulin concentrate trea-
ted groups. 
Figure 7. The effect of immunoglobulin concentrate fed on first two feedings on 
the serum complement activities of calves during the first 30 days of life. Bars 
represent estimated means ±SE.
Growth 5.4   inhibition of H. pylori by L. plantarum 
MLBPL1 (IV) 
The inhibitory effect of culture supernatants of seven L. plantarum -related 
lactobacilli against H. pylori was screened by measuring the diameters of in-
hibitory zones on plate. All members of the L. plantarum group showed some 
anti-Helicobacter activity, but the culture supernatants of the strains L. plan-
tarum MLBPL1, isolated from sauerkraut, and L. pentosus from a commercial 
starter Vege-Start 60 showed the clearest inhibition. The inhibitory activities of   
MLBPL1 cells cultivated in cucumber juice, carrot juice or whey were similar 
to the inhibitory activity of MLBPL1 cells cultivated in MRS broth. In addition 
0 
10 
20 
30 
40 
Age days 
S
e
r
u
m
 
t
i
t
r
e
 
o
f
 
L
D
-
5
0
%
 
10 
20 
30 
40 
50 
60
2  7  14  30  2  7  14  30 
Classical pathway of complement  Alternative pathway of complement
Control  Treat1  Treat2 44
to the culture supernatant, whole cells as well as cell lysate and cell wall frag-
ments of L. plantarum MLBPL1 contained anti-Helicobacter activity. The int-
racellular fraction did not significantly inhibit the growth of Helicobacter.
The active substance of the culture supernatant from a MRS-grown L. planta-
rum MLBPL1 culture was concentrated by ammonium sulphate precipitation. 
This precipitate retained its anti-Helicobacter activity after 10 min treatment 
at 100°C, and at neutral pH, whereas the crude culture supernatant lost its acti-
vity if pH was raised. It was not possible to remove the anti-Helicobacter acti-
vity of MLBPL1 precipitate by incubation with any of the proteolytic enzymes 
tested. On the contrary, incubation with N-glycosidase F slightly increased the 
anti-Helicobacter activity of MLBPL1. The substance with anti-Helicobacter 
activity in the cell-free culture supernatant was found to be between 3,000 and 
10,000 daltons in size. 
Reduction of the adherence of  5.5  H. pylori and S. 
mutans by colostral preparations and live LAB 
(III, V)
Fresh milk and toddler’s milk based drink without IP slightly enhanced the ad-
herence of S. mutans to saliva-coated hydroxyapatite, but products containing 
anti-caries-IP displayed significantly lower adherence of S. mutans to saliva-co-
ated hydroxyapatite. There were no marked differences between different tem-
peratures. IP with specific H. pylori antibodies, but also CP reduced the adhe-
sion of H. pylori on AGS-cells in a dose-dependent way. The anti-adhesive ac-
tivity was present also when the complement system of colostral preparations 
was inactivated by heating, but not as strong as with active IP and CP. 
LGG-fermented milk without antibodies also inhibited the adherence of S. mu-
tans by about 40% (Figure 8). This inhibition was dependent on the presence of 
LGG cells in milk since the supernatant of these milk samples did not inhibit 
adherence. However, there was a trend that LGG-fermented milk containing IP 
was even more effective (P = 0.062) in preventing adherence of S. mutans than 
LGG-fermented milk without IP in spite of decline in specific antibody titres. 
The presence or absence of HEPES buffer did not affect these adhesion pheno-
me but the number of viable LGG cells remained higher (over 108 cfu/ml) du-
ring the long storage period if no HEPES was added (III).
Live lactobacilli reduced the adhesion of H. pylori on AGS cells by approxima-
tely 50% when LAB concentration was 1010cfu/ml (p<0.05). Heat killed LAB 
had a non-significant effect on adhesion. 
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Figure 8. Effects of L. rhamnosus GG fermented milks on the adherence of S. 
mutans to salivacoated hydroxyapatite compared with saliva alone (approx. 
1x108 cells adhered; taken as 100%). IP=immune preparation, H= HEPES 
and GG= L. rhamnosus GG, Milk=fresh milk. Bars represent estimated me-
ans ±SE.
Reduction in the IL-8 production of AGS cells  5.6 
after infection by H. pylori pretreated with live 
lactobacilli or colostral preparations (V)
IL-8 concentration in the growth medium of AGS cells after 20 h incubation 
was 540±150 pg/ml. After the infection of AGS cells by H. pylori the IL-8 le-
vel rose up to about 10 fold (5500±1600 pg/ml) (Figure 9). The presence of IP, 
CP, or live LAB did not affect the IL-8 levels produced by uninfected AGS 
cells. On the contrary, heat killed LAB at a concentration of 1010/ml raised the 
IL-8 level of uninfected AGS cells significantly. Pretreatment of H. pylori with 
live L. plantarum MLBPL1, LGG, or Lactococcus lactis cells before infecti-
on of AGS cells prevented the IL-8 rise when concentration of added LAB was 
1010/ml (p<0.0001) (Figure 9a). The prevention was also statistically significant 
with LGG at a concentration of 109/ml (p=0.0382), and L. lactis at concentra-
tions of 109/ml (p=0.0026) and 108/ml (p=0.0116). The heat-inactivated LAB 
were shown to be less effective in reducing the IL-8 production induced by H. 
pylori infection in AGS cells than live LAB (Figure 9b). IP and CP also lowe-
red the IL-8 level of AGS cells infected with Helicobacter back to the normal 
p=0.062 46
level. Heat inactivated CP needed a higher concentration than the other colost-
ral samples for this reduction.
Figure 9. The IL-8 production of AGS-cells treated for 20 hours with H. py-
lori and live (a) or heat killed (b) lactic acid bacteria (LAB) at concentrations 
from 104 to 1010cfu/ml. Levels of IL-8 (pg/ml) in the culture medium of AGS-
cells were determined by ELISA test. Bars represent estimated means ±SE; n= 
2-6.  ___ Lactobacillus plantarum MLBPL1, .. _ ..  Lactobacillus rhamnosus GG,   
- - - Lactococcus lactis.
The effect of specific antibodies of IP in the  5.7 
prevention and treatment of an experimental 
H. felis infection (II) 
All mice in the infected control group in Trial 1, 70% in Trial 2, and 79% in 
Trial 3 were H. felis positive, whereas all animals in the healthy control groups 
remained H. felis negative. The levels of H. felis antibodies in the sera of mice 
correlated well with the presence or absence of H. felis infection but not with 
the degree of colonization or inflammation in the gastric antrum. The SJL strain 
developed more severe inflammation and a higher grade of H. felis colonization 
than Balb/c mice used in Trial 1.
The IP had a significant (P=0.0014) preventive effect on H. felis infection, gi-
ven the absence of visible bacteria in gastric antra and corpusa. In the group re-
ceiving prophylactic immune preparation (IP) H. felis bacteria were detected in 
7 out of 17 mice (41%), whereas all the mice given control preparation or PBS 
were infected (Table 8). 
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Table 8. Prevention of experimental Helicobacter felis infection in mice with co-
lostral immune preparation.
Rate (%) of infection
H. felis positive H. felis negative p values
immune preparation 41% 59% 0.0014
control preparation 100% - n.s.
infected controls 100% -
The administration of colostral preparations did not eradicate an established H. 
felis infection. A slight decrease of H. felis colonization and of the degree of in-
flammation of the gastric antrum was observed, but not in all trials (Table 9).
A two-week treatment with IP had a significant (P=0.029) and with CP a trend-
setting (P=0.091) reducing effect on H. felis colonization of the antra in Trial 1. 
However, only two of the 19 mice treated with IP were H. felis negative while 
all the mice treated with CP remained H. felis positive. 
The only therapeutic effect on infected SJL mice was seen in animals treated 
with IP containing both specific antibodies and active serum complement in 
Trial 2 but not in Trial 3 (Table 9). In this group (Trial 2) the grade of inflam-
mation in antrum was lower than in the infected controls. In the other treatment 
groups there was a tendency towards a heavier H. felis colonization as compa-
red to infected controls. In the corpusa of mice treated with complement inacti-
vated IP or serum supplemented CP the grade of colonization was significantly 
higher. The removal of small molecules from IP did not abolish the effect inc-
reasing H. felis colonization even though the increasing effect of IgG was not 
statisitically significant (p=0.13).
A 6-day treatment with amoxicillin decreased the grade of H. felis colonizati-
on in antrum with a trend-setting (P=0.056) significance when compared to in-
fected controls. The combination of filtered and serum supplemented immune 
preparation, and amoxicillin treatment resulted in a significant (P=0.0005) dec-
rease in the colonization of antrum. The difference between these two groups 
was not significant. 48
Table 9. Effect of colostral immune preparation and complement on H. felis in-
fection in mice as compared to infected controls. 
Treatment Trial Colonization Inflammation
corpus antrum antrum
IP 1 n.s. ↓ * n.s.
CP 1 n.s. ↓ o n.s.
IP + complement (NBS) 2 n.s. n.s. (↑) ↓ o
CP + complement (NBS) 2 ↑* n.s. n.s.
Complement inactivated IP 2 ↑* n.s. (↑) n.s.
Complement inactivated CP 2 n.s. (↑) n.s. (↑) n.s.
Complement (NBS) 2 n.s. (↑) n.s. n.s.
IP + complement (NBS) 3 n.s. ↑* n.s. (↑)
IgG of IP + complement 
(NBS)
3 n.s. n.s. (↑) n.s. (↑)
Amoxicillin 3 n.s. ↓ o n.s. (↓)
IgG of IP + NBS + amoxicil-
lin 
3 n.s. ↓ *** ↓**
↓= reduction, ↑= increase. ° p<0.1, * p<0.05, ** p<0.01, *** p<0.001, n.s. 
= statistically non-significant. IP= colostral immune preparation with specific 
Helicobacter felis antibodies, CP= colostral control preparation, NBS= normal 
bovine serum.49
Discussion 6 
The role of colostral complement in gastroin- 6.1 
testinal infections
In the present study the efficacies of colostral immunoglobulin preparations 
and selected lactic acid bacteria on gastrointestinal infections were investiga-
ted. The regulation of complement activity by colostrum is of vital importance 
for the health of a calf. In study (I) it was demonstrated that the ingestion of co-
lostral immunoglobulin concentrate increases the complement and opsonisati-
on activities in the sera of neonatal calves. As the concentration of complement 
component C3 was not higher in the sera of calves supplemented with colostral 
concentrate than in the sera of control calves, it was concluded that no conside-
rable amounts of complement C3 protein was transferred from the cow to the 
calf by absorption from colostrum. 
Enterotoxigenic E. coli is a common cause of diarrhea and other infectious di-
seases in calves during the first weeks of life. The E. coli strains JM103 sensiti-
vite to complement and IH3080 resistant to complement lysis were used in study 
(I) as model organisms. They are not known to be natural pathogens of calves 
but the complement and opsonization activities against these strains reflect well 
the functions of serum complement and antibodies against bacterial pathogens 
in general. Antibody-dependent, naturally occurring bactericidal complement 
activity has a significant role against coliform infections in calves (Carroll and 
Crensaw 1976). Ingestion of colostral immunoglobulin concentrate increased 
the level of E. coli specific antibodies in the blood, and thus caused the higher 
activity in the classic pathway of complement (I). 
The cause for the higher activity of the antibody-independent alternative path-
way of the complement system as well as a higher opsonisation capacity in the 
calves fed immunoglobulin concentrate was supposed to be the complement 
proteins and/or lectins. Mannose-binding lectin (MBL) is able to trigger the 
lectin pathway of complement activation by binding to sugar groups on the pat-
hogen surface (Turner 1996). Also, bovine conglutinin is known to show opso-
nizing activity towards E. coli (Holmskov 2000). MBL is present in human co-
lostrum (Trégoat et al. 2002). H. pylori activates the lectin pathway of comple-
ment (Kuipers 2003). MBL deficiency does, however, not increase the risk of 
chronic gastritis associated with H. pylori infection (Bak-Romaniszyn et al. 
2006, Worthley et al. 2007). 
The antibody-complement system of bovine colostrum is known to kill H. py-
lori effectively (Korhonen et al. 1995, Early et al. 2001). This bacteriolytic ac-
tivity was also present in our colostral preparations (II), which killed H. pylori 50
in vitro. In study (II) the effects of inactivation and supplementation of the se-
rum derived complement system in the treatment of H. felis infection was te-
sted in a mouse model. IP and CP supplemented with serum as a source for ac-
tive complement system did, however, not decrease the rate of H. felis coloni-
zation. In one of the trials IP supplemented with serum reduced the degree of 
inflammation in the antra of H. felis infected mice, but this result could not be 
repeated in the next trial. However, the results obtained support the suggestion 
that an active complement system might be important for the efficacy of the IP 
in the treatment of gastritis. 
Colostral antibodies in protection against in- 6.2 
fections
Colostral immunoglobulins are an essential part of the protection of calves 
against infections as the serum of a newborn calf is essentially free of immu-
noglobulins. The E. coli-specific antibody levels in the sera of calves fed im-
munoglobulin concentrate (I) correlated with the total IgG concentrations in 
the sera as reported by Nousiainen et al. (1994). In study (II) it was demonstra-
ted that more than 25% of antibodies were active after 30 min incubation in a 
simulated gastric juice containing HCl and pepsin at pH 4.0. It can thus be as-
sumed that in humans a substantial proportion of administered bovine IgG1 re-
mains immunologically active long enough to reach the gastric mucosa and to 
attach to Helicobacter. Further, the pH of gastric juice of gastritis patients trea-
ted with proton pump inhibitors is often relatively high, and immunoglobulins 
have been recovered in their gastric juice (Meining et al. 2002). 
In mice, the administration of colostral preparations did not eradicate an estab-
lished H. felis infection, but the treatment with IP reduced the H. felis colonizati-
on in the antra of Balb/c mice, the CP giving a rather similar but statistically less 
significant result (II). In study (II) there was a tendency towards a higher H. felis 
colonization rate in mice treated with IP than in infected controls. It was sugge-
sted that milk components others than immunoglobulins might be responsible 
for this effect. However, concentration of the immunoglobulin fraction in order 
to abolish the H. felis colonization increasing effect did not have any effect. 
In study (II) it was tested whether the IP could enhance the effect of the tre-
atment of Helicobacter infection with an inadequate antibiotic dosage. The IP 
supplemented with serum and combined with amoxicillin lowered the levels of 
inflammation and colonization significantly as compared to the infected cont-
rols whereas the treatment with amoxicillin alone had a trend setting effect on 
colonization and none on inflammation. 
The IP with specific anti-Helicobacter antibodies was able to protect the mice 
against experimental H. felis infection (II). This preventive effect could not be 51
demonstrated in the mice receiving CP concluding that the preventive effect is 
dependent on the presence of specific antibodies. Similar IP with specific anti-
caries antibodies used in study (III) inhibited the adherence of cariogenic strep-
tococci to saliva-coated hydroxyapatite beads, and CP had a significantly lower 
effect than IP. However, according to results in study (V), both IP and CP redu-
ced H. pylori adhesion to AGS cells in a dose dependent manner, and there was 
no significant difference between IP and CP. 
In studies (I, II, III and V) we found that other antimicrobial factors than anti-
bodies and complement system are involved in the protection against infections. 
Dietary factors are reported to influence the severity of Helicobacter-induced 
gastritis and gastric cancer, low intake of vegetables and fruit, and high intakes 
of salt and processed meat being risk factors (Rocco and Nardone 2007, Epplein 
et al. 2008). Bovine lactoferrin or lactoferrin plus probiotics added to triple the-
rapy improved the eradication rates in the treatment of H. pylori infection (Di 
Mario et al. 2003, de Bortoli et al. 2007). Lysozyme and lactoperoxidase also 
act against pathogens (Pakkanen and Aalto 1997, Zimecki and Kruzel 2007). 
Milk components such as κ-casein (Vacca-Smith et al. 1994), caseinomacro-
peptide also called glycomacropeptide, and caseinophosphopeptide (Schupbach 
et al. 1996) may reduce the adherence of S. mutans and S. sobrinus. However, 
the fresh milk and UHT milk products in our study slightly enhanced bacte-
rial adherence (III). Similarly, in the study by Shimazaki et al. (2001) the num-
ber of S. mutans cells in saliva and plaque increased in the control group recei-
ving nonimmune milk. The mechanism for the dose dependent anti-adhesion 
mechanism of IP and CP in the study (V) is suggested to be in other colostral 
components than specific antibodies against H. pylori. Also factors related to 
the properties of the host, or the type or phase of the infection may influence 
the efficacy of IP (II). 
The idea for combining IP and probiotic bacteria was for the first time introdu-
ced in study (II). Recently, Pant et al. (2007) reported about a successful prophy-
lactic use of a combination of probiotic L. rhamnosus GG and specific colostral 
antibodies against rotavirus in a mouse model.
LAB in prevention of caries and  6.3  H. pylori infection
The anti-Helicobacter activity of seven LAB strains belonging to the L. planta-
rum group was screened in vitro (IV). All members of the L. plantarum group 
showed some anti-Helicobacter activity, but the culture supernatants of the 
strains L. plantarum MLBPL1, isolated from sauerkraut, and L. pentosus from 
a commercial starter Vege-Start 60 showed the clearest inhibition. 
In this study, the active substance of L. plantarum MLBPL1 was further cha-
racterized. Even though lactic acid inhibits the urease activity of H. pylori, se-52
veral studies have shown other substances secreted by LAB to be behind the 
mechanism of antibacterial effects (Hamilton-Miller 2003, Coconnier et al. 
1998, Michetti et al. 1999). The substance with anti-Helicobacter activity in the 
culture supernatant of L. plantarum MLBPL1 was found to be between 3000 
and 10 000 Daltons in size (IV). Thus, the effect of organic acids and other low 
molecular mass compounds was excluded. The anti-Helicobacter activity was 
heat resistant and retained its activity at neutral pH. According to the results, 
the main activity seemed to be associated with the cell wall, from where it is 
probably extracted into culture supernatant. It was not possible to remove the 
anti-Helicobacter activity of MLBPL1 by incubation with proteolytic enzymes. 
Therefore, it seems that the anti-Helicobacter effect observed is not explained 
by an already known bacteriocin. On the contrary, incubation with N-glycosi-
dase F increased the anti-Helicobacter activity of MLBPL1, suggesting that a 
component of a larger molecule could be the active compound, which gains the 
full activity after cleavage from a carrier substance. Further studies are, howe-
ver, needed to identify the active compound.
LGG is known to inhibit the growth of cariogenic streptococci by producing 
antistreptococcal substances (Meurman et al. 1995). The inability of LGG to 
ferment sucrose or lactose limits its growth in milk but greatly increases its po-
tential as a food probiotic against cariogenic streptococci, particularly if com-
bined with specific antibodies against S. mutans and S. sobrinus as shown in 
(III). LGG is also known to adhere on human gastric epithelial cells (Tuomola 
and Salminen 1998). L. plantarum MLBPL1, LGG and L. lactis were all able 
to prevent H. pylori adhesion on AGS cells and suppress the IL-8 production 
of H. pylori infected AGS cells similarly independent of their ability to adhe-
re to gastric epithelium (V). L. johnsonii La1 and L. acidophilus strain LB sec-
rete heat-stable substances able to decrease H. pylori adhering to gastric cells 
(Michetti et al. 1999, Coconnier et al. 1998). In the study (V), however, the heat 
inactivation of LAB cells reduced the anti-adhesive activity. This suggests the 
occurrence of another anti-adhesive mechanism in addition to those secreted 
components. 
The effect of colostral preparations and LAB  6.4 
on inflammatory response
In spite of effectiviness of IP in passive immunization (II) the role of antibodies 
is apparently only marginal for the protective immunity in Helicobacter infec-
tion, the cellular immunity being more important. The production of IL-8 by 
gastric epithelial cells plays a significant role in the initial response to H. pylori 
infection by promoting inflammation and tissue damage locally and attracting 
leucocytes to the sites of inflammation (O’Keeffe and Moran 2008). In the study 
(V) the suppressive effect of bovine colostral preparations on the IL-8 produc-53
tion by H. pylori induced AGS cells was demonstrated. The reduction of IL-8 
production might have caused the slight decrease in the degree of inflammati-
on of the gastric antrum observed in Helicobacter infected mice treated with 
IP in study (II). Colostral preparations were effective in reducing the H. pylori 
induced IL-8 production also at low concentrations.
Live LAB did not affect the IL-8 levels of uninfected AGS cells. Reduction in 
IL-8 concentration by LAB happened only after H. pylori infection. This sug-
gests that LAB act on IL-8 secretion induced by H. pylori infection in the host 
cell. It is known that lactobacilli can affect the IL-8 production of intestinal 
epithelial cells in vitro, when IL-8 secretion is stimulated with TNF-α. Other 
studies have also demonstrated that LAB do not affect IL-8 production without 
the recruitment of proinflammatory cytokines (Ko et al. 2007, McCracken et 
al. 2002, Zhang et al. 2005). We also showed that heat killed LAB had a weak 
suppressive effect on IL-8 production of H. pylori infected cells, but increased 
the IL-8 level of uninfected AGS cells (V). Together, these results suggest that 
the active factor affecting the immune response of AGS cells might be in the 
cell wall material of heat killed LAB. Live LAB were more effective in redu-
cing H. pylori induced IL-8 production in host cells than heat inactivated, sug-
gesting that physiological response from LAB is required to suppress H. pylo-
ri induced IL-8 activation.
Control of bacterial adhesion and IL-8 production by LAB or colostral products 
could have a suppressive effect on Helicobacter infection by reducing pro-in-
flammatory cytokine expression and thus avoiding a chronic inflammation. 
Some technological aspects on the use of IP  6.5 
and LAB
Bovine milk is a good medium for functional products containing, for examp-
le, specific antibodies. The colostral preparations are composed mainly on pro-
teins, the majority being IgG (Table 7). The rest of colostral preparations consist 
of sugars and minerals (data not shown). The specific antibodies retained their 
activity for more than 10 years when stored at –18°C like shown also by Pant et 
al. (2007). In study (III) when IP was stored in UHT milk at different tempe-
ratures, the pH and the IgG concentration remained stable for up to 2 months. 
ELISA test and adherence assay provided further evidence that the specific anti-
bodies in UHT milk also remain functionally active during the storage. We also 
found that the metabolism of LGG did not influence the number of antibodies 
during fermentation. Both fermented and unfermented IP could significantly in-
hibit the adherence of S. mutans, as could normal LGG-fermented milk (III). 
Several factors, such as utilization of IgG as a substrate for bacterial growth 
(Jansen et al. 1994) or proteolytic cleavage of IgG (Brock et al. 1977, de Rahm 54
and Isliker 1977), may contribute to reductions in IgG activities. The degrada-
tion of IgG1 is also dependent on temperature. Foley et al. (1978) reported only 
minimal breakdown of IgG during fermentation, as also found in our study in 
the presence of LGG. The fact that the antibody titres declined during storage 
in fermented milk (III) may be related to the metabolism of LGG and the sub-
sequent pH decline in IP. 
The anti-Helicobacter activity of several probiotic LAB strains used in dairy 
products has been reported in a number of in vitro studies and clinical trials, and 
the results have been encouraging (Hamilton-Miller 2003). The majority of the 
LAB tested for anti-Helicobacter activity has been exemplars of species with 
minor importance as starters or strains used for probiotic purposes. Techno-
logical properties of commercial probiotic culture preparations are often prob-
lematic. They are sensitive, and may affect the sensory properties of the prod-
uct. So, it is common to add them to a completed product. On the contrary, L. 
plantarum has been traditionally used for acidification of foodstuffs and can be 
used as starter in the production of a wide variety of fermented foods. In study 
(IV), the anti-Helicobacter activity was present also in cultivations performed 
in different food matrices. Consequently, the production of a fermented food 
with anti-Helicobacter activity would be easy and cost-efficient, because no 
additional components besides the food matrix and the starter culture will be 
needed to complete the process. 
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Conclusions and future aspects 7 
In the present study bovine colostral antibodies and lactic acid bacteria as me-
ans to control gastrointestinal infections were investigated in vitro and in ani-
mal models. The main results and conclusions of the study were:
In neonatal calves, complement and opsonization activities of serum were  • 
increased substantially by feeding colostral whey concentrate. 
Specific •   colostral antibodies effectively prevented Helicobacter infection 
in a mouse model but they were not able to eradicate an established Heli-
cobacter infection. Colostral antibodies seemed to increase the therapeutic 
effect of amoxicillin on H. felis infection.
Colostral antibodies retained their activity when stored in UHT-milk drink  • 
or fermented with LGG. Combining specific colostral antibodies and pro-
biotics proved promising in preventing the adherence of S. mutans to sali-
va-coated hydroxyapatite.
Anti- •  Helicobacter activity was found in seven strains belonging to L. 
plantarum group. The activity of L. plantarum MLBPL1 was located to 
cell wall.
LAB and colostral preparations were able to inhibit the adhesion of  •  H. py-
lori in a cell model, and to suppress IL-8 production by H. pylori infected 
AGS cells.
In future, the combining of LAB and IP needs to be further studied. However, 
the authorities in European Union limit the use of IP in food as products con-
taining antibodies are considered as drugs. Products, supplemented by speci-
fic bovine colostral antibodies or LAB, might be useful in the prevention of hu-
man dental decay during early childhood, or in the prevention of Helicobacter 
infection in endemic areas. IP could also contribute beneficially to the effect of 
the antibiotics and alleviate the inflammatory effects in clinically asymptomatic 
subjects infected by H. pylori and, in the best case, suppress the development of 
a chronic inflammation. Further in vivo studies are, however, needed to verify 
the beneficial effects of LAB and IP on gastrointestinal infections.56
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